• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Haemonetics (HAE) Is Back In The Spotlight, What Is The Market Watching?

    Simply Wall St·10/08/2026 01:34:12
    Listen to the news

    Haemonetics (HAE) has drawn fresh attention after recent share moves, with the price closing at US$101.71. Investors are weighing this level against the company’s fundamentals and recent return profile.

    Recent trading has been choppy, with the Haemonetics share price slipping 1.8% over one day and 3.4% over the past week, yet the 90 day share price return of 35.6% and 1 year total shareholder return of 99.5% indicate strong underlying momentum.

    Spot other potential momentum stories alongside Haemonetics by scanning our hand picked 29 high quality undervalued stocks that combine strong recent returns with solid underlying fundamentals.

    Bulls see Haemonetics as a quality medtech business with fresh momentum, while bears see a hot chart that has run ahead of itself. Which side do the current valuation markers lean toward next?

    Most Popular Narrative: 9% Undervalued

    Haemonetics is being framed by the most followed narrative as modestly undervalued, with a fair value of $111.50 compared with the last close at $101.71. That view leans heavily on execution in plasma technology, hospital systems and margin resilience rather than on short term price moves.

    The main factor that needs to work in the company’s favor is that NexSys with Persona PLUS, TEG 6s disposables, and vascular closure products continue to convert clinical evidence, contract wins, and recurring revenue into sustained growth despite tariff and leverage headwinds.

    See why 8 investors see Haemonetics as 9% undervalued.

    Result: Fair Value of $111.50 (UNDERVALUED)

    Still, the Haemonetics story could change quickly if leverage near 2.7x EBITDA bites during a slowdown or if tariff and cost pressures squeeze margins harder than expected.

    Find out about the key risks to this Haemonetics narrative.

    Another View: Haemonetics On Earnings Multiples

    Haemonetics may look appealing on narrative and DCF style fair value work, yet the earnings multiple tells a tougher story. The stock trades on a P/E of 48.1x, almost double the US Medical Equipment industry at 24.5x and well above a fair ratio of 32x.

    That spread suggests investors are already paying a premium for execution. If sentiment cools and the market leans closer to peer levels or the fair ratio, how much room is left in the share price before that premium gets questioned.

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:HAE P/E Ratio as at Oct 2026
    NYSE:HAE P/E Ratio as at Oct 2026

    Next Steps

    The mix of enthusiasm and caution around Haemonetics can feel hard to balance, so consider acting promptly, reviewing the underlying data, and weighing the 2 key rewards and 3 important warning signs.

    Hunting For More Ideas Beyond Haemonetics?

    If you like the setup around Haemonetics, do not stop here. Broaden your watchlist with fresh ideas filtered by quality, resilience, and upside potential using the Simply Wall Street Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.